Biomarker-Based Metabolic Labeling for Redirected and Enhanced Immune Response

Li, Shanshan; Yu, Bingchen; Wang, Jiajia; Zheng, Yueqin; Zhang, Huajie; Walker, Margaret J.; Yuan, Zhengnan; Zhu, He; Zhang, Jun; Wang, Peng George; Wang, Binghe

doi:10.1021/acschembio.8b00350

Cited by 37 publications

(36 citation statements)

References 75 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Unsurprisingly, glycoengineering represents an enabling technology for various biomedical applications, namely, both live cell, and extracellular vesicle labeling/tracking, drug‐based cancer theranostics, as well as cell‐based chemo‐ and immunotherapies . Despite an impressive body of literature on these recent advances, tissue engineering concepts exploiting this biomachinery phenomenon are still at their youth.…”

Section: Cell‐rich Assembliesmentioning

confidence: 99%

Advanced Bottom‐Up Engineering of Living Architectures

et al. 2019

View full text Add to dashboard Cite

Bottom‐up tissue engineering is a promising approach for designing modular biomimetic structures that aim to recapitulate the intricate hierarchy and biofunctionality of native human tissues. In recent years, this field has seen exciting progress driven by an increasing knowledge of biological systems and their rational deconstruction into key core components. Relevant advances in the bottom‐up assembly of unitary living blocks toward the creation of higher order bioarchitectures based on multicellular‐rich structures or multicomponent cell–biomaterial synergies are described. An up‐to‐date critical overview of long‐term existing and rapidly emerging technologies for integrative bottom‐up tissue engineering is provided, including discussion of their practical challenges and required advances. It is envisioned that a combination of cell–biomaterial constructs with bioadaptable features and biospecific 3D designs will contribute to the development of more robust and functional humanized tissues for therapies and disease models, as well as tools for fundamental biological studies.

show abstract

Section: Cell‐rich Assembliesmentioning

confidence: 99%

Advanced Bottom‐Up Engineering of Living Architectures

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The azido group can serve as a handle for further labeling for imaging and immune therapy applications. 97 In K562 cells, it took twice as much time for the mono-and disubstituted analogs to complete the cleavage as compared to the unsubstituted one. By combining this monosubstituted disulfide linker system and a MPP, mitochondrial delivery of an HSP90 inhibitor was achieved.…”

Section: Thiol-sensitive Linkersmentioning

confidence: 99%

“…Ac4ManNAz incubation can lead to azidomannose incorporation into cell surface sialic acid. The azido group can serve as a handle for further labeling for imaging and immune therapy applications 97 . In K562 cells, it took twice as much time for the mono‐ and disubstituted analogs to complete the cleavage as compared to the unsubstituted one.…”

Section: Thiol‐sensitive Linkersmentioning

confidence: 99%

Making smart drugs smarter: The importance of linker chemistry in targeted drug delivery

Yang

Pan

Choudhury

et al. 2020

Medicinal Research Reviews

Self Cite

View full text Add to dashboard Cite

Smart drugs, such as antibody-drug conjugates, for targeted therapy rely on the ability to deliver a warhead to the desired location and to achieve activation at the same site. Thus, designing a smart drug often requires proper linker chemistry for tethering the warhead with a vehicle in such a way that either allows the active drug to retain its potency while being tethered or ensures release and thus activation at the desired location. Recent years have seen much progress in the design of new linker activation strategies. Herein, we review the recent development of chemical strategies used to link the warhead with a delivery vehicle for preferential cleavage at the desired sites. K E Y W O R D S antibody-drug conjugates, click and release, drug delivery, linker chemistry, targeted delivery, triggered release 1 | INTRODUCTION In the world of drug discovery and development, the concept of "smart drugs" broadly refers to those that can selectively affect disease-relevant target(s). However, to a certain degree, essentially all drugs are already selective toward the desired target(s) whether they are enzyme inhibitors, receptor ligands, ion channel blockers, inhibitors of protein-protein interaction, or even genotoxins used for cancer chemotherapy, among others. They would not have made through the various milestones of drug discovery and developmental processes if they were not sufficiently selective for the intended target(s). However, once administered into the human body, the highly complex living system often leads to many unexpected off-target effects. Thus, various additional approaches have been studied and

show abstract

“…Redirecting these antibodies to target specic disease cells could lead to adaptive immunities for selective and effective therapy. [31][32][33][34][35][36][37] For instance, a pioneering work from McNaughton's group demonstrated that DNP-modied nanobody 5F7 could recruit anti-DNP antibodies to HER2 + cancer cells and elicit a specic ADCC effect in vitro. However, no in vivo studies have been reported yet.…”

Section: Introductionmentioning

confidence: 99%